MedTrace Logo

Hepatitis C Treatment Study in Myanmar

NCT03158857 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-12-17

No results posted yet for this study

Summary

Hepatitis C is an important health problem in Myanmar affecting around 3% of the population. New drugs have been developed which have transformed the treatment of this disease around the world with very high success rates. Two of these drugs are now registered for use in Myanmar. In this study 200 patients with chronic hepatitis C(100 with HIV co-infection) will be assessed and started on the new treatment. We will observe them and measure treatment effectiveness and tolerability. In 24 patients extra blood samples will be taken for drug measurements to describe the effect of the drugs on patients in Myanmar in more detail.

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir 400 mg

These drugs are being offered as part of routine care

Sponsors & Collaborators

  • Myanmar Liver Foundation

    collaborator OTHER

  • Medical Action Myanmar

    collaborator OTHER

  • Myanmar Oxford Clinical Research Unit

    lead OTHER

Principal Investigators

  • Ni Ni Tun, MB BS · Medical Action Myanmar; MOCRU

  • Khin Pyone Kyi, MB BS · Myanmar Liver Foundation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • Burma

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03158857 on ClinicalTrials.gov